Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.21 | N/A |
Market Cap | $38.94M | N/A |
Shares Outstanding | 185.43M | 10.84% |
Employees | 50.00 | N/A |
Shareholder Equity | 48.23M | -36.66% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.81 | N/A |
P/B Ratio | 0.81 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.7258 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$35.01M | N/A |
EPS | -0.26 | N/A |
Earnings Yield | -1.24 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $39.73M | N/A |
Cash on Hand | $12.26M | N/A |
Debt to Equity | 0.0865 | 13.06% |
Current Ratio | $4.09 | -44.52% |